预约演示
更新于：2026-06-23
Muvalaplin
穆伐普林
更新于：2026-06-23
概要
基本信息
原研机构 |
在研机构 |
权益机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评突破性疗法 (中国) |
登录后查看时间轴
结构/序列
分子式C42H54N4O6 |
InChIKeyBRLGERLDHZRETI-BGBFCPIGSA-N |
CAS号2565656-70-2 |
关联
7
项与 穆伐普林 相关的临床试验NCT07157774
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Muvalaplin on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Had a Prior Atherosclerotic Cardiovascular Event or Are at Risk for a First Atherosclerotic Cardiovascular Event
NCT06342596
A Phase 1, Open-Label, Two-Part Study of the Disposition and Absolute Bioavailability of [14C]-LY3473329 in Healthy Male Participants
NCT05778864
Pharmacokinetics of LY3473329 Following Oral Administration in Participants With Renal Impairment Compared With Participants With Normal Renal Function
100 项与 穆伐普林 相关的临床结果
登录后查看更多信息
100 项与 穆伐普林 相关的转化医学
登录后查看更多信息
100 项与 穆伐普林 相关的专利（医药）
登录后查看更多信息
14
项与 穆伐普林 相关的文献（医药）2026-06-01CARDIOVASCULAR DRUGS AND THERAPY
Lipoprotein(a) in Cardiovascular Diseases and Emerging Therapeutic Strategies
Review
作者: Smith, Emily Lauren Schenk ; Selico-Dunn, Alexandra C ; Al-Horani, Rami A
Abstract:
Purpose:
Lipoprotein(a) [Lp(a)] is increasingly recognized as a genetically determined, independent risk factor for atherosclerotic cardiovascular disease (ASCVD). This review examines the structure, pathophysiology, and epidemiology of Lp(a), with a focus on its contribution to ASCVD and related conditions such as aortic valve stenosis and peripheral artery disease. The main research question addresses how Lp(a) influences cardiovascular risk and how emerging therapies may modify this risk.
Methods:
This review synthesizes published evidence describing the biological characteristics of Lp(a), its mechanistic roles in disease, and its epidemiologic associations with cardiovascular outcomes. It also evaluates current and investigational therapeutic approaches by examining clinical trial data for agents targeting Lp(a).
Results:
Lp(a) contributes to residual cardiovascular risk through proatherogenic, proinflammatory, and prothrombotic mechanisms. Current evidence highlights its involvement in ASCVD, aortic valve stenosis, and peripheral artery disease. Clinical studies of antisense oligonucleotides, small interfering RNAs, oral small molecules, and CRISPR-based gene editing, including pelacarsen, olpasiran, zerlasiran, lepodisiran, muvalaplin, and obicetrapib, demonstrate promising efficacy and safety. These agents show potential to significantly reduce Lp(a) levels and influence future cardiovascular prevention strategies.
Conclusion:
As novel therapies advance and clinical guidelines evolve, Lp(a) is emerging as a central determinant in personalized cardiovascular care. The increasing emphasis on Lp(a) testing underscores its importance in risk stratification and future therapeutic decisionmaking.
2026-05-01PHARMACOLOGICAL RESEARCH
Comparative efficacy and safety of novel Lp(a)-lowering therapies for ASCVD prevention: A network meta-analysis
Review
作者: Wang, Xing-Jin ; Li, Yi ; Hu, Jia-Qiang ; Xu, Ying ; Li, Jin-Wei ; Liu, Song ; Wu, An-Xin ; Zhao, Chen
Elevated lipoprotein(a) [Lp(a)] is a genetically determined and independent risk factor for atherosclerotic cardiovascular disease (ASCVD) that is largely resistant to conventional lipid-lowering therapies. Novel Lp(a)-targeted agents, including small interfering RNA (siRNA), antisense oligonucleotides (ASO), and the oral small-molecule inhibitor muvalaplin, have shown potent efficacy in early trials. We conducted a systematic review and network meta-analysis to comprehensively compare their efficacy and safety. A total of 25 randomized controlled trials (RCTs) involving 7715 participants were included, evaluating six siRNA agents, four ASO agents, and one small-molecule inhibitor. The primary outcome was percentage change from baseline in Lp(a). Secondary outcomes included absolute change in Lp(a), percentage changes in apolipoprotein B (apoB) and low-density lipoprotein cholesterol (LDL-C), and adverse events. SiRNA therapies achieved the greatest Lp(a) reductions (olpasiran: mean difference [MD] -92.1%, 95% CI -100.1 to -84.0%; zerlasiran: -80.6%, 95% CI -87.7 to -73.5%), followed by muvalaplin (-76.8%, 95% CI -90.3 to -63.2%) and ASO therapy (pelacarsen: -54.2%, 95% CI -72.2 to -36.2%; all P < 0.001). Most agents achieved absolute Lp(a) reductions exceeding 105 nmol/L, suggesting clinically meaningful benefit. Baseline Lp(a) levels significantly modified treatment response (P < 0.001), and concomitant proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor use further enhanced LDL-C reduction (P = 0.024). All therapies were well tolerated, with injection-site reactions most frequent for injectables, while muvalaplin was well tolerated. These findings indicate that targeted Lp(a)-lowering therapies substantially reduce circulating Lp(a), with siRNA showing the greatest potency and muvalaplin offering a convenient oral alternative for personalized ASCVD risk reduction.
2026-01-21Cardiovascular & hematological disorders drug targets
Muvalaplin: A Novel Oral Therapy for Targeted Reduction of Plasma Lipoprotein(a)
Article
作者: Lange, Richard ; Botros, Monica ; Tiji, Michelle
Plasma lipoprotein(a) [Lp(a)] levels greater than 50 mg/dL are an independent risk
factor for cardiovascular diseases, including heart failure, atherosclerosis, and aortic valve stenosis.
Lp(a) exhibits proatherogenic properties by promoting vascular inflammation, thrombosis,
and calcification. Several therapeutic agents specifically designed to reduce Lp(a) formation are
currently under evaluation in clinical trials or regulatory review. Muvalaplin is notable as the
first orally administered drug developed to lower plasma Lp(a) levels. This review evaluates the
efficacy, safety, and tolerability of muvalaplin and compares its profile with other Lp(a)-
lowering agents. A systematic literature search was conducted using the PubMed database for
articles published between 2020 and 2025, with keywords, including muvalaplin, lipoprotein,
and cardiovascular. Only original research, clinical trials, and review articles were included.
Muvalaplin is an oral small-molecule inhibitor being studied as the first oral Lp(a)-lowering
agent. In Phase I trials, daily administration of muvalaplin for 14 days reduced Lp(a) levels by
up to 65%. In Phase II trials, 12 weeks of daily muvalaplin resulted in reductions of up to 86% in
Lp(a) levels without significant safety or tolerability concerns. These findings suggest that muvalaplin
could be a valuable therapeutic option for managing cardiovascular risk associated with
elevated Lp(a). Notably, unlike other Lp(a)-lowering agents, muvalaplin did not cause skinrelated
adverse events at injection sites. Although the initial clinical data are promising, Phase III
trials are required to establish long-term safety and determine whether reductions in plasma
Lp(a) translate into meaningful reductions in cardiovascular events.
100 项与 穆伐普林 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 外周动脉疾病 | 临床3期 | 中国 | 2025-09-19 | |
| 动脉粥样硬化 | 临床3期 | 美国 | 2025-09-02 | |
| 动脉粥样硬化 | 临床3期 | 中国 | 2025-09-02 | |
| 动脉粥样硬化 | 临床3期 | 日本 | 2025-09-02 | |
| 动脉粥样硬化 | 临床3期 | 阿根廷 | 2025-09-02 | |
| 动脉粥样硬化 | 临床3期 | 澳大利亚 | 2025-09-02 | |
| 动脉粥样硬化 | 临床3期 | 奥地利 | 2025-09-02 | |
| 动脉粥样硬化 | 临床3期 | 比利时 | 2025-09-02 | |
| 动脉粥样硬化 | 临床3期 | 巴西 | 2025-09-02 | |
| 动脉粥样硬化 | 临床3期 | 加拿大 | 2025-09-02 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 233 | (10 mg LY3473329) | 醖憲衊獵選範鹽鑰鹹餘(廠顧獵襯觸衊襯積鏇淵) = 築網窪願繭壓網築蓋襯 廠鹽願獵簾醖衊醖衊鹹 (夢餘膚鏇觸餘齋築齋憲, 4.811) 更多 | - | 2025-03-25 | ||
(60 mg LY3473329) | 醖憲衊獵選範鹽鑰鹹餘(廠顧獵襯觸衊襯積鏇淵) = 鬱範鹽觸膚醖鏇築鏇窪 廠鹽願獵簾醖衊醖衊鹹 (夢餘膚鏇觸餘齋築齋憲, 1.230) 更多 | ||||||
临床2期 | - | 餘獵窪鬱窪願齋獵憲艱(壓鏇衊淵夢窪鹹範窪齋) = 願獵蓋網餘艱鑰鑰蓋築 積艱鏇觸衊齋鏇壓淵糧 (觸壓醖膚廠齋襯鑰顧襯 ) 达到 更多 | 积极 | 2024-11-18 | |||
餘獵窪鬱窪願齋獵憲艱(壓鏇衊淵夢窪鹹範窪齋) = 願醖餘襯網願觸製簾艱 積艱鏇觸衊齋鏇壓淵糧 (觸壓醖膚廠齋襯鑰顧襯 ) 达到 更多 | |||||||
临床2期 | 233 | 壓衊鑰繭遞繭鬱憲淵鹽(糧窪艱構鬱願觸觸鬱積) = 窪廠獵願鬱範製構艱醖 鹹遞鑰顧夢願餘餘艱艱 (廠齋醖鏇製觸願繭顧網, -2.2% ~ 18.8%) 更多 | 积极 | 2024-11-18 | |||
壓衊鑰繭遞繭鬱憲淵鹽(糧窪艱構鬱願觸觸鬱積) = 鹹艱淵壓糧遞積選憲選 鹹遞鑰顧夢願餘餘艱艱 (廠齋醖鏇製觸願繭顧網, 4.4% ~ 20.9%) 更多 | |||||||
临床1期 | 105 | 醖餘獵顧襯齋餘製齋窪(淵願網膚積範艱廠簾夢) = 膚鏇餘鬱蓋簾鏇壓壓鹽 遞觸窪餘繭鏇糧鹹鏇壓 (糧簾遞鬱襯鑰衊範鹹壓 ) 更多 | 积极 | 2023-08-28 | |||
Placebo | - |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用